8,000 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,000 shares of the company’s stock, valued at approximately $465,000.

A number of other large investors have also recently bought and sold shares of KROS. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. bought a new stake in Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics during the second quarter worth about $128,000. Ameritas Investment Partners Inc. grew its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares during the last quarter. Finally, Quest Partners LLC grew its stake in Keros Therapeutics by 23,945.0% during the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after buying an additional 4,789 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They set an “overweight” rating on the stock. Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective on the stock. Scotiabank began coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Finally, Bank of America cut their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $89.11.

Keros Therapeutics Price Performance

Shares of KROS opened at $59.95 on Tuesday. The firm has a 50-day moving average of $56.53 and a 200-day moving average of $51.86. Keros Therapeutics, Inc. has a one year low of $27.31 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period in the previous year, the business posted ($1.27) earnings per share. As a group, analysts expect that Keros Therapeutics, Inc. will post -4.9 EPS for the current year.

Insider Buying and Selling

In related news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.90% of the stock is currently owned by insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.